BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30758911)

  • 1. Infective endocarditis in two patients with pemphigus vulgaris under multiagent immunosuppressive drug therapy: A rare entity to remember in the differential diagnosis of fever of unknown origin.
    Küçükoğlu R; Kılıç S; Sun GP
    Dermatol Ther; 2019 May; 32(3):e12860. PubMed ID: 30758911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil as adjuvant in pemphigus vulgaris.
    Sarma N; Ghosh S
    Indian J Dermatol Venereol Leprol; 2007; 73(5):348-50. PubMed ID: 17921620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunesuppressive treatment of Pemphigus vulgaris as a predisposing factor for native valve endocarditis: report of two cases.
    Kayrak M; Bacaksiz A; Gul EE; Sonmez O
    J Heart Valve Dis; 2011 May; 20(3):360-1. PubMed ID: 21714432
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.
    Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Luger TA
    Arch Dermatol; 2006 Nov; 142(11):1447-54. PubMed ID: 17116835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
    Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
    Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.
    Doukaki S; Platamone A; Alaimo R; Bongiorno MR
    J Dermatolog Treat; 2015 Feb; 26(1):67-72. PubMed ID: 24521072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris].
    Chams-Davatchi C; Nonahal Azar R; Daneshpazooh M; Valikhani M; Hallaji Z; Barzegari M; Firouz AR; Zakeri M
    Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):23-5. PubMed ID: 11937925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris.
    Koga H; Ishii N; Hamada T; Karashima T; Nakama T; Yasumoto S; Hashimoto T
    Eur J Dermatol; 2010; 20(4):472-5. PubMed ID: 20406724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris.
    Baskan EB; Yilmaz M; Tunali S; Saricaoglu H
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1432-4. PubMed ID: 19470052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
    Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
    Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
    Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ
    An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
    España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
    Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
    Kim MR; Kim HC; Kim SC
    Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate is effective in the treatment of pemphigus vulgaris.
    Enk AH; Knop J
    Arch Dermatol; 1999 Jan; 135(1):54-6. PubMed ID: 9923781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differential diagnosis of infective endocarditis and fevers of unrelated genesis].
    Korytnikov KI
    Klin Med (Mosk); 2001; 79(5):27-9. PubMed ID: 11510180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Life-threatening course of pemphigus vulgaris complicated by sepsis caused by azathioprine-induced bone marrow suppression, successfully managed with combination therapy.
    Tichy M; Urbanek J; Sternbersky J; Ditrichova D; Hercogova J
    Dermatol Ther; 2014; 27(3):183-6. PubMed ID: 24283408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemphigus vulgaris treated with adalimumab: case study.
    Vojáčková N; Fialová J; Vaňousová D; Hercogová J
    Dermatol Ther; 2012; 25(1):95-7. PubMed ID: 22591504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemphigus in Korea: clinical manifestations and treatment protocol.
    Seo PG; Choi WW; Chung JH
    J Dermatol; 2003 Nov; 30(11):782-8. PubMed ID: 14684934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the usefulness of mycophenolate mofetil in pemphigus.
    Powell AM; Albert S; Al Fares S; Harman KE; Setterfield J; Bhogal B; Black MM
    Br J Dermatol; 2003 Jul; 149(1):138-45. PubMed ID: 12890207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.